SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-22-012395 to O2MICRO INTERNATIONAL LTD (CIK 0001095348)

O2MICRO INTERNATIONAL LTD (CIK 0001095348)
Date: Nov. 15, 2022 · CIK: 0001095348 · Accession: 0000000000-22-012395

AI Filing Summary & Sentiment

Date
November 15, 2022
Author
Not clearly detected
Form
UPLOAD
Company
O2MICRO INTERNATIONAL LTD (CIK 0001095348)

Letter

United States securities and exchange commission logo November 15, 2022 Peter Huang, Esq. Partner Skadden, Arps, Slate, Meagher & Flom LLP 30/F, China World Office 2 No. 1, Jianguomenwai Avenue Chaoyang District Beijing 100004 People’s Republic of China Re:O2Micro International Limited Schedule 13E-3 filed by O2Micro International Limited et al. Filed October 31, 2022 File No. 005-61085 Dear Peter Huang: We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to these comments by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response. After reviewing your response to these comments, we may have additional comments. All defined terms used herein have the same meaning as in the preliminary statement. Schedule 13E-3 Filed October 31, 2022 Background of the Merger, page 17 1.Refer to the first paragraph on page 19. Disclosure in this paragraph indicates that "Needham updated the Special Committee on the status of its financial analyses, including certain preliminary valuation considerations, and discussed....the potential market check and bidder outreach process." We also note at the the May 17, 2022, June 7, 2022, and July 21, 2022, meetings Needham "updated the Special Committee on the progress of its financial analyses." Each presentation, discussion, or report held with or presented by the financial advisor, whether oral or written, is a separate report that requires a reasonably detailed description meeting the requirements of Item 1015 of Regulation M-A. This

FirstName LastNamePeter Huang, Esq. Comapany NameSkadden, Arps, Slate, Meagher & Flom LLP November 15, 2022 Page 2 FirstName LastName Peter Huang, Esq. Skadden, Arps, Slate, Meagher & Flom LLP November 15, 2022 Page 2 requirement applies to both preliminary and final reports. If the above statements reference presentations made by Needham during the Special Committee's evaluation of the transaction, please supplement the disclosure to provide a reasonable detailed description of such meeting that satisfices the requirements of Item 1015 and file any written materials, if applicable, as exhibits to the Schedule 13E-3 pursuant to Item 9 of Schedule 13E-3 and Item 1016(c) of Regulation M-A. Certain Financial Projections, page 33 2.Refer to the assumptions on page 34 marked with bullet points, including without limitation, references to:

•implement strategic focus on LED television, mobile computing, general lighting, industrial and automtive •the gross margin as percentage will increase •research and development expense •selling, general and administrative

Please revise the disclosure to quantify all assumptions, where practicable. 3.Please disclose the material factors that the Company expected to negatively impact growth prospects as discussed in (ii) on page 35. Opinion of the Special Committee's Financial Advisor, page 36 4.The Discussion Materials filed as Exhibit (c)-(2) of Schedule 13E-3 should be summarized in considerable detail in the proxy statement. See Item 1015(b)(6) of Regulation M-A and Item 9 of Schedule 13E-3. Please revise this section to disclose the data underlying the results in each analysis prepared by Needham and to show how that information resulted in the multiples/values disclosed. As one example only, disclose the public companies valuation analysis starting on page 16. We remind you that the filing persons are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please direct any questions to Michael Killoy at 202-551-7576 or Daniel Duchovny at 202-551-3619. Sincerely, Division of Corporation Finance Office of Mergers & Acquisitions

Show Raw Text
United States securities and exchange commission logo
November 15, 2022
Peter Huang, Esq.
Partner
Skadden, Arps, Slate, Meagher & Flom LLP
30/F, China World Office 2
No. 1, Jianguomenwai Avenue
Chaoyang District
Beijing 100004
People’s Republic of China
Re:O2Micro International Limited
Schedule 13E-3 filed by O2Micro International Limited et al.
Filed October 31, 2022
File No. 005-61085
Dear Peter Huang:
            We have reviewed your filing and have the following comments. In some of our
comments, we may ask you to provide us with information so we may better understand your
disclosure.
            Please respond to these comments by providing the requested information or advise us as
soon as possible when you will respond. If you do not believe our comments apply to your facts
and circumstances, please tell us why in your response.
            After reviewing your response to these comments, we may have additional comments.
All defined terms used herein have the same meaning as in the preliminary statement.
Schedule 13E-3 Filed October 31, 2022
Background of the Merger, page 17
1.Refer to the first paragraph on page 19.  Disclosure in this paragraph indicates that
"Needham updated the Special Committee on the status of its financial analyses, including
certain preliminary valuation considerations, and discussed....the potential market check
and bidder outreach process." We also note at the the May 17, 2022, June 7, 2022, and
July 21, 2022, meetings Needham "updated the Special Committee on the progress of its
financial analyses."  Each presentation, discussion, or report held with or presented by the
financial advisor, whether oral or written, is a separate report that requires a reasonably
detailed description meeting the requirements of Item 1015 of Regulation M-A.  This

 FirstName LastNamePeter Huang, Esq.
 Comapany NameSkadden, Arps, Slate, Meagher & Flom LLP
 November 15, 2022 Page 2
 FirstName LastName
Peter Huang, Esq.
Skadden, Arps, Slate, Meagher & Flom LLP
November 15, 2022
Page 2
requirement applies to both preliminary and final reports.  If the above statements
reference presentations made by Needham during the Special Committee's evaluation of
the transaction, please supplement the disclosure to provide a reasonable detailed
description of such meeting that satisfices the requirements of Item 1015 and file any
written materials, if applicable, as exhibits to the Schedule 13E-3 pursuant to Item 9 of
Schedule 13E-3 and Item 1016(c) of Regulation M-A.
Certain Financial Projections, page 33
2.Refer to the assumptions on page 34 marked with bullet points, including without
limitation, references to:

•implement strategic focus on LED television, mobile computing, general lighting,
industrial and automtive
•the gross margin as percentage will increase
•research and development expense
•selling, general and administrative

Please revise the disclosure to quantify all assumptions, where practicable.
3.Please disclose the material factors that the Company expected to negatively impact
growth prospects as discussed in (ii) on page 35.
Opinion of the Special Committee's Financial Advisor, page 36
4.The Discussion Materials filed as Exhibit (c)-(2) of Schedule 13E-3 should be
summarized in considerable detail in the proxy statement.  See Item 1015(b)(6) of
Regulation M-A and Item 9 of Schedule 13E-3.  Please revise this section to disclose the
data underlying the results in each analysis prepared by Needham and to show how that
information resulted in the multiples/values disclosed.  As one example only, disclose
the public companies valuation analysis starting on page 16.
            We remind you that the filing persons are responsible for the accuracy and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please direct any questions to Michael Killoy at 202-551-7576 or Daniel Duchovny at
202-551-3619.
Sincerely,
Division of Corporation Finance
Office of Mergers & Acquisitions